摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-butane-1,4-diamine | 1381786-73-7

中文名称
——
中文别名
——
英文名称
N-(2-chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-butane-1,4-diamine
英文别名
N'-(2-chloro-6-methylpyrimidin-4-yl)-N-(7-chloroquinolin-4-yl)butane-1,4-diamine
N-(2-chloro-6-methyl-pyrimidin-4-yl)-N'-(7-chloro-quinolin-4-yl)-butane-1,4-diamine化学式
CAS
1381786-73-7
化学式
C18H19Cl2N5
mdl
——
分子量
376.288
InChiKey
ZCXMXBQKDWNZLN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    25
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    62.7
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel 4-Aminoquinoline-Pyrimidine Based Hybrids with Improved in Vitro and in Vivo Antimalarial Activity
    作者:Sunny Manohar、U. Chinna Rajesh、Shabana I. Khan、Babu L. Tekwani、Diwan S. Rawat
    DOI:10.1021/ml3000808
    日期:2012.7.12
    hybrid molecules consisting of 4-aminoquinoline and pyrimidine were synthesized and tested for antimalarial activity against both chloroquine (CQ)-sensitive (D6) and chloroquine (CQ)-resistant (W2) strains of Plasmodium falciparum through an in vitro assay. Eleven hybrids showed better antimalarial activity against both CQ-sensitive and CQ-resistant strains of P. falciparum in comparison to standard
    合成了一类由 4-氨基喹啉和嘧啶组成的杂交分子,并通过体外试验测试了对氯喹 (CQ) 敏感 (D6) 和氯喹 (CQ) 抗性 (W2)恶性疟原虫菌株的抗疟活性。11 个杂种对恶性疟原虫的CQ 敏感和 CQ 抗性菌株显示出更好的抗疟活性与标准药物 CQ 相比。在 D6 菌株中,四个分子比 CQ 更有效(7-8 倍),并且发现八个分子对抗性菌株(W2)的活性高 5-25 倍。几种化合物在高达高浓度 (60 μM) 时没有表现出任何细胞毒性,其他化合物表现出轻微的毒性,但对于大多数这些杂种而言,抗疟活性的选择指数非常高。选择用于体内评估的两种化合物在伯氏疟原虫小鼠模型中显示出优异的活性 (po),没有任何明显的毒性。还测定了其中一种化合物的 X 射线晶体结构。
  • AMINOQUINOLINE DERIVATIVES AND USES THEREOF
    申请人:THE MCLEAN HOSPITAL CORPORATION
    公开号:US20150023930A1
    公开(公告)日:2015-01-22
    Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
    本文描述了基于氨基喹啉和氨基蒽醌的混合物,包括含有这种基于氨基喹啉和氨基蒽醌的混合物的制药组合物和药物,以及使用这种化合物诊断和/或治疗感染、神经退行性疾病或障碍、炎症、与炎症相关的疾病和障碍以及可用多巴胺激动剂治疗的疾病或障碍(如不宁腿综合征)的方法。
  • Aminoquinoline derivatives and uses thereof
    申请人:UNIVERSITY OF DELHI
    公开号:US11026943B2
    公开(公告)日:2021-06-08
    Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
    本文描述了基于氨基喹啉和氨基吖啶的混合物、包括这种基于氨基喹啉和氨基吖啶的混合物的药物组合物和药物,以及使用这种化合物诊断和/或治疗感染、神经退行性疾病或紊乱、炎症、炎症相关疾病和紊乱和/或可使用多巴胺激动剂治疗的疾病或紊乱(如不安腿综合征)的方法。
  • Aminoquinoline Derivatives and Uses Thereof
    申请人:The McLean Hospital Corporation
    公开号:US20220008418A1
    公开(公告)日:2022-01-13
    Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
  • US9567316B2
    申请人:——
    公开号:US9567316B2
    公开(公告)日:2017-02-14
查看更多